The Insider Activity Of Alaunos Therapeutics Inc. (TCRT) Is Worth Monitoring


Alaunos Therapeutics Inc. (NASDAQ:TCRT) finished Thursday with a subtraction of -$0.13 to close at $1.88, a downside of -6.47 percent. An average of 9,676,880 shares of common stock have been traded in the last five days. There was a fall of -$0.23 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 7,713,915 shares traded, while the 50-day average volume stands at 4,064,866.

TCRT stock has increased by 10.59% in the last month. The company shares reached their 1-month lowest point of $1.26 on 09/15/22. With the stock rallying to its 52-week high on 09/09/22, shares of the company touched a low of $0.41 and a high of $4.01 in 52 weeks. It has reached a new high 20 times so far this year and achieved 72.48% or $0.79 in price. In spite of this, the price is down -53.12% from the 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Valuation Metrics

Alaunos Therapeutics Inc. (TCRT) stock’s beta is 0.15. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 857.47, the price-to-book (PB) ratio at 9.89.

Financial Health

The quick ratio of Alaunos Therapeutics Inc. for the three months ended March 30 was 2.30, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.11 and a total debt to equity ratio of 0.61 for the quarter ending March 30. Its gross profit as reported stood at $77.95 million compared to revenue of $0.4 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Alaunos Therapeutics Inc.’s return on assets was -59.00%.

Earnings Surprise

For the three-month period that ended March 30, Alaunos Therapeutics Inc. had $4.47 million in total debt. The company posted a net income of -$9.93 million in the quarter, while revenues of -$9.79 million were shrunk -128.3%. The analyst consensus anticipated Alaunos Therapeutics Inc.’s latest quarter earnings to come in at -$0.07 per share, but it turned out to be -$0.05, a 28.60% surprise. For the quarter, EBITDA amounted to -$8.34 million. Shareholders own equity worth $216.18 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Alaunos Therapeutics Inc. (TCRT) price momentum. RSI 9-day as of the close on 22 September was 33.43%, suggesting the stock is Neutral, with historical volatility in this time frame at 265.88%.

As of today, TCRT’s price is $2.28 -10.90% or -$0.23 from its 5-day moving average. TCRT is currently trading -7.84% lower than its 20-day SMA and +253.78% higher than its 100-day SMA. However, the stock’s current price level is +27.89% above the SMA50 and +49.21% above the SMA200.

The stochastic %K and %D were 32.12% and 38.95%, respectively, and the average true range (ATR) was 0.56. With the 14-day stochastic at 22.55% and the average true range at 0.49, the RSI (14) stands at 40.29%. The stock has reached -0.51 on the 9-day MACD Oscillator while the 14-day reading was at -0.74.

Analyst Ratings

The consensus rating for Alaunos Therapeutics Inc. (TCRT) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TCRT, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.

What is TCRT’s price target for the next 12 months?

Analysts predict a range of price targets between $2.00 and $7.50, with a median target of $3.50. Taking a look at these predictions, the average price target given by analysts for Alaunos Therapeutics Inc. (TCRT) stock is $4.20.


Please enter your comment!
Please enter your name here